A settlement was reached with the defendants in the lawsuit filed on behalf of certain investors of Enzymotec Ltd (NASDAQ:ENZY) over alleged securities laws violations and a deadline to submit the settlement claim is upcoming on December 26, 2017 and NASDAQ:ENZY investors should contact the Shareholders Foundation.
San Diego, CA -- (SBWIRE) -- 12/05/2017 -- The Shareholders Foundation announces that a deadline is coming up on December 26, 2017 in the settlement reached in the securities class action lawsuit filed on behalf of investors who purchased shares of Enzymotec Ltd (NASDAQ:ENZY) between September 27, 2013 and August 4, 2014.
Investors who purchased a significant amount of shares of Enzymotec Ltd (NASDAQ:ENZY) between September 27, 2013 and August 4, 2014, have certain options and should contact the Shareholders Foundation by email at firstname.lastname@example.org or call 858-779-1554.
The settlement proof of claim form or detailed settlement notice for the settlement in the Enzymotec Ltd (NASDAQ:ENZY) Investor Securities Class Action Lawsuit can be downloaded at: http://shareholdersfoundation.com/case/enzymotec-ltd-nasdaq-enzy-investor-securities-class-action-lawsuit-09052014
In order to submit a claim an investor has to submit the claim proof to the class action claim administrator in a timely manner. The deadline to submit the proof with the class administrator is December 26, 2017. The class action administrator for this case is Enzymotec Securities Litigation.
The lawsuit was originally filed in the U.S. District Court for the District of New Jersey over alleged violations of Federal Securities Laws by Enzymotec Ltd in connection with certain allegedly false and misleading statements made in regards of Enzymotec Ltd's initial public offering on or about September 27, 2013 and August 4, 2014. According to the complaint the plaintiff alleges on behalf of purchasers of Enzymotec Ltd (NASDAQ:ENZY) securities pursuant and/or traceable to Enzymotec Ltd's Registration Statement and Prospectus issued in connection with Enzymotec Ltd's initial public offering ("IPO") on or about September 27, 2013, and/or on the open market between September 27, 2013 and August 4, 2014, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that the Registration Statement and Prospectus allegedly contained materially false and misleading statements and omitted material information, and that defendants misrepresented and/or failed to disclose between September 27, 2013 and August 4, 2014:
- that Enzymotec Ltd's Chinese business was subject to material and readily identifiable compliance regulations from the Chinese government,
- that Enzymotec Ltd's baby formula business in China was jeopardized and subject to increased volatility and decreased revenues,
- that Enzymotec Ltd's joint venture with AarhusKarlshamn AB, which marketed the popular InFat product, was crumbling and subjected the Company to liability and decreased revenues, and
- that Defendants' positive statements about Enzymotec Ltd's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
Those who purchased shares of Enzymotec Ltd (NASDAQ:ENZY) have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego